Press release
Cystic Fibrosis (CF) Market Report | Emerging Biopharma Players & Clinical Pipeline Updates | Gilead sciences, Alcresta Therapeutics Inc, Merck & Co. Inc, Pfizer Inc, Genentech, Chiesi Pharmaceuticals B.V
Cystic Fibrosis Market
Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://datamintelligence.com/download-sample/cystic-fibrosis-market?kb
Latest M&A in Cystic Fibrosis
4D Molecular Therapeutics (4DMT) received $11 million in additional funding from the Cystic Fibrosis Foundation to advance its gene therapy candidate 4D-710 for CF treatment, entering Phase 2 trials in 2025.
Major pharmaceutical M&A in 2025 include large deals in metabolic and rare diseases, impacting CF research investments indirectly.
Venture capital and private equity continue funding CF-focused biotech startups developing novel CFTR modulators and gene therapies.
List of Top Key Player:
Novartis AG, Vertex Pharmaceuticals Inc, F. Hoffmann-La Roche Ltd, Teva Pharmaceutical Industries Ltd, Gilead sciences, Alcresta Therapeutics Inc, Merck & Co. Inc, Pfizer Inc, Genentech, Chiesi Pharmaceuticals B.V.
Latest News & Market Trends
The US CF therapeutics market was valued at around $2.32 billion in 2024 and is expected to grow to $4.72 billion by 2033 driven by advances in CFTR modulators and gene therapy.
Several clinical trials are underway testing new therapies addressing chronic lung infections, inflammation, and gene correction.
A novel inhaled antibiotic combination (RSP-1502) pioneered in Western Australia showed promising Phase 1b results and entered Phase 2 trials to treat lung infections in CF patients.
Generic versions of inhaled tobramycin, an antibiotic for bacterial lung infections in CF, received FDA approval in November 2025, expanding access.
Forecast Projection:
The Global Cystic Fibrosis Market is poised for significant growth between 2025 and 2032. In 2024, the market maintained a steady upward trajectory, and with strategic initiatives by leading players accelerating adoption, the market is expected to soar throughout the forecast period. Companies leveraging these trends are well-positioned to capture emerging opportunities and maximize revenue potential.
Market Intelligence Research Process:
The Cystic Fibrosis Market research report by DataM Intelligence combines primary and secondary data to deliver deep, actionable insights. It examines the full spectrum of factors shaping the industry, from government regulations and market conditions to competitive dynamics, historical trends, technological breakthroughs, upcoming innovations, and potential challenges. This comprehensive analysis not only highlights growth prospects but also identifies barriers, equipping businesses to navigate market volatility and capitalize on emerging opportunities.
Buy Now & Get 30% OFF - (Grab 50% OFF on 2+ reports) @ https://www.datamintelligence.com/buy-now-page?report=cystic-fibrosis-market?kb
Key Segmentation:
By Drug Class: (CFTR Modulators, Antibiotics, Pancreatic Enzyme Supplements, Mucolytics, Bronchodilators, Others)
By Route of Administration: (Oral, Inhaled, Parenteral)
By Distribution Channel: (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
Global Growth Regional Analysis:
⇥ North America (U.S., Canada, Mexico)
⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
⇥ South America (Colombia, Brazil, Argentina, Rest of South America)
⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)
Latest FDA Approvals
FDA granted approval to Vertex Pharmaceuticals' Alyftrek for CF patients aged 6 and older with common CFTR mutations in 2024-2025 and continues expanding indications.
Generic tobramycin inhalation solution approved by FDA in late 2025 provides an affordable option for CF lung infection treatment.
Other pipeline approvals focus on CFTR modulators, anti-inflammatory agents, and gene therapies.
Get Customization in the report as per your requirements: https://datamintelligence.com/customize/cystic-fibrosis-market?kb
Reimbursement Updates
Belgium extended full reimbursement of Kaftrio (CFTR modulator) to children aged 2 to 5 years starting February 2025, with clinical trials ongoing for younger babies.
Global reimbursement frameworks are adapting to novel gene therapies and CF treatments, balancing high drug costs with long-term health benefits.
Insurance coverage is progressively improving access for CF patients worldwide, supported by advocacy groups.
Have any Query We Will Provide in Detailed @ https://www.datamintelligence.com/enquiry/cystic-fibrosis-market?kb
Drugs Related to Cystic Fibrosis
Key CF drugs include CFTR modulator combinations like Trikafta (elexacaftor/tezacaftor/ivacaftor), Kaftrio, and the newly approved Alyftrek.
Antibiotics like inhaled tobramycin and novel antibiotic boosters like RSP-1502 address chronic lung infections common in CF.
Gene therapies (4D-710) and anti-inflammatory agents are in development to expand therapeutic options.
Get 2-Day Free Trial + 50% OFF DataM Subscription@ https://www.datamintelligence.com/reports-subscription?kb
Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.
Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg
Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com
About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Cystic Fibrosis (CF) Market Report | Emerging Biopharma Players & Clinical Pipeline Updates | Gilead sciences, Alcresta Therapeutics Inc, Merck & Co. Inc, Pfizer Inc, Genentech, Chiesi Pharmaceuticals B.V here
News-ID: 4253367 • Views: …
More Releases from DataM Intelligence 4 Market Research LLP
United States Induction Motor Market 2031 | Growth Drivers, Trends & Market Fore …
Induction Motor Market size was worth US$ 20.36 billion in 2023 and is estimated to reach US$ 33.66 billion by 2031, growing at a CAGR of 6.49% during the forecast period (2024-2031).
Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/induction-motor-market?kb
List of Top Key Player:
ABB Ltd., Ametek, Emerson Electric, Siemens AG, Brook Crompton, Danaher Corporation, Johnson Electric Holdings, Regal Beloit, WEG Electric Corp.…
Digital Therapeutics Market Set for Explosive Growth to USD 39.52 Billion by 203 …
The Global Digital Therapeutics Market size reached USD 6.84 billion in 2024 and is expected to reach USD 39.52 billion by 2033, growing at a CAGR of 21.6% during the forecast period 2025-2033.
Market growth is driven by the rising prevalence of chronic diseases like diabetes and mental health disorders, increasing smartphone penetration, and growing patient demand for personalized, app-based interventions. Advancements in AI and machine learning for behavior change, expanding…
United States Contrast Media Injectors Market: Real-Time Market Trends & Competi …
DataM Intelligence unveils its latest report on the "Contrast Media Injectors Market Size 2025," offering an in-depth analysis of market trends, growth drivers, competitive landscape, and regional dynamics. The study covers market size in value and volume, CAGR forecasts, and emerging opportunities that can guide businesses in seizing growth potential and crafting winning strategies. Packed with data-driven insights on current developments and future trends, this report is essential for companies…
United States Real Time Location System (RTLS) Market Analysis 2026: Growth Driv …
Real Time Location System (RTLS) Market is expected to grow at a CAGR of 18% during the forecasting period (2022-2029).
Request a Premium Sample PDF of This Report (Corporate Email IDs Receive Priority Service): https://www.datamintelligence.com/download-sample/real-time-location-system-market?kb
United States: Recent Industry Developments
✅ December 2025: Major healthcare systems expanded RTLS deployments to enhance patient tracking, asset utilization, and workflow efficiency.
✅ November 2025: Leading tech providers integrated AI‐driven analytics into RTLS platforms to deliver predictive…
More Releases for Cystic
Cystic Fibrosis Market Report-Growth with Industry Study, Detailed Analysis | Cy …
The research study contains an in detail descriptive overview and analysis of the Cystic Fibrosis Market, a summary of the market shares constituted by each component, the annual growth of each sector, and the revenue potential of the section. In addition, Cystic Fibrosis Market production and consumption data are used to determine the geographical features.
Get FREE PDF sample of the Report @ https://www.reportsnreports.com/contacts/requestsample.aspx?name=3639856
Top Company Profile Analysis in this Report-
Cystic Fibrosis…
The Cystic Fibrosis Market to Witness Robust Growth Due to Increasing Cases of C …
Cystic fibrosis is a rare, progressive, life-threatening disease results in the formation of thick mucus that builds up in the lungs, digestive tract, and other parts of the body. If left untreated, it leads to severe digestive and respiratory problems as well as other complications such as infections and diabetes. According to the Cystic Fibrosis Foundation, more than 70,000 people are living with cystic fibrosis around the world. As the…
Cystic Fibrosis Therapeutics Market Research Reports 2017
This report studies sales (consumption) of Cystic Fibrosis Therapeutics in Europe market, especially in Germany, France, UK, Russia, Italy, Spain and Benelux, focuses on top players in these countries, with sales, price, revenue and market share for each player in these Countries, covering
Vertex Pharmaceuticals , F. Hoffmann-La Roche , AbbVie , Gilead Science , Novartis , AstraZeneca , Bayer , Celtaxsys , Pharmaxis , ProQR Therapeutics , PTC Therapeutics…
Cystic Fibrosis Market - Global Industry Analysis 2024
Cystic fibrosis (CF) is a genetic disorder that usually affects the lungs and may also affect the pancreas, kidneys, liver, and intestine. Long-term repercussions including difficulty in breathing and coughing as a result of recurrent lung infections can be seen in CF. Some of the other signs and symptoms include sinus infections, poor growth, infertility in males, fatty stool, and guild of the fingers and toes. Different individuals may have…
Cystic Fibrosis - Heat Map and Analysis
ReportsWorldwide has announced the addition of a new report title Cystic Fibrosis - Heat Map and Analysis to its growing collection of premium market research reports.
Cystic fibrosis (CF) is a progressive genetic condition and is the result of a patient inheriting a faulty cystic fibroses transmembrane conductance regulator (CFTR) gene from both parents. The defective CFTR genes produce faulty CFTR proteins on the body’s epithelial cells, and result in…
Cystic Fibrosis - Heat Map And Analysis
MarketResearchReports.Biz is providing you Latest Market Research report of "Cystic Fibrosis - Heat Map And Analysis".
Cystic fibrosis (CF) is a progressive genetic condition and is the result of a patient inheriting a faulty cystic fibroses transmembrane conductance regulator (CFTR) gene from both parents. The defective CFTR genes produce faulty CFTR proteins on the body?s epithelial cells, and result in the buildup of a thick and sticky mucus in the lungs…
